Research programme: mGlu receptor modulators - SelvitaAlternative Names: SEL203
Latest Information Update: 12 Nov 2014
At a glance
- Originator Selvita
- Mechanism of Action Metabotropic glutamate receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Fragile X syndrome; Parkinson's disease
Most Recent Events
- 12 Nov 2014 Early research in Parkinson's disease in Poland (unspecified route)
- 12 Nov 2014 Early research in Fragile X syndrome in Poland (unspecified route)